GTOnco™ Immuno-Oncology Assay Services
With professional service and various advanced equipment at Creative Biolabs, GTOnco™ platform provides high-quality preclinical profiling and monitoring of immune responses for the gene therapy-based I-O drug development. Utilizing the most effective combination of assays available to identify promising I-O therapeutics, our broad range of well-established assays and animal models allow clients to choose the most appropriate study design and screening method to identify the best option and optimize lead candidates. GTOnco™ platform allows you to rapidly identify single agent or combinations that affect tumor cell lysis, T cell proliferation and polarization, and natural killer (NK) cell function.
GTOnco™ I-O Assays for In Vitro Study
It is necessary to collect sufficient product characterization data for clinical development. Creative Biolabs has leveraged the cutting-edge technologies to build a groundbreaking platform for in vitro immune responses analysis of gene therapy-based I-O agents, including immune system activation study (T and B cells, natural killer cells, macrophages, and dendritic cells, as well as tumor cells) and immune cell-mediated anti-tumor effect study, etc. Multiple approaches have been developed and assessed by enzyme-linked immunosorbent assay (ELISA) and/or western blot and/or qPCR and/or flow cytometry and/or other methods of assessment.
GTOnco™ I-O Assays for In Vivo Study
Various robust animal models and assay systems have been successfully established at GTOnco™ platform to greatly facilitate the in vivo studies of gene therapy-based I-O products with less time and cost. In order to provide a model system that enables researchers to study the immune system and assess the immune cell-mediated anti-tumor response of I-O agents, syngeneic mouse tumor models with fully immune-competent hosts and humanized mouse models (HIS) have been developed in-house. We offer a variety of effective syngeneic cell line derived models for your research on I-O drug discovery in gene therapy. We also provide multiplex technologies such as flow cytometry, RT-qPCR, and ELISpot, immunohistochemistry or immunohistofluorescence-based imaging to analyze anti-tumor immune response profiling. Our experienced scientists are able to help you design the best assays for customized in vivo studies.
Creative Biolabs is specialized in gene therapy-based I-O drugs development and capable of designing and developing custom assay services to greatly accelerate your drug discovery process and expedite their IND application. With the in-depth scientific and technical expertise, we will be your best partner in the gene therapy-based I-O drugs development field. Please feel free to contact us by E-mail for a quote and further discussion with our scientists. Looking forward to cooperating with you.
References
- Pérez, P.; et al. (2018). A Vaccine Based on a Modified Vaccinia Virus Ankara Vector Expressing Zika Virus Structural Proteins Controls Zika Virus Replication in Mice. Scientific Reports, 8(1).
- Yu, F.; et al. (2014). T-cell Engager-armed Oncolytic Vaccinia Virus Significantly Enhances Antitumor Therapy. Molecular Therapy, 22(1), pp.102-111.
- Velcheti, V. and Schalper, K. (2016). Basic Overview of Current Immunotherapy Approaches in Cancer. American Society of Clinical Oncology Educational Book, (36), pp.298-308.
